Lazard Upgrades ArthroCare (ARTC) to Buy
More News related to ARTC
- ArthroCare Announces Decision from NASDAQ Granting Its Request for Continued Listing and Announces Extension of Deadline to Deliver Financial Statements under Its Credit Agreement
- ArthroCare Receives Expected Additional NASDAQ Staff Determination Letter Regarding Delayed Filing of Form 10-Q; NASDAQ Panel Decision Remains Pending
- ArthroCare (ARTC) Sees Upside Move, Possibly On SEC Short Rules
- Lazard Upgrades ArthroCare (ARTC) to Buy
- JANA Partners 13F Shows New Stakes in Genentech (DNA), Sears (SHLD), Washington Mutual (WM); Adds to Positions in AK Steel (AKS), Focus Media (FMCN), Transocean (RIG); Sells Out of Apple (AAPL), Lehma
More News related to Upgrades
- What's Next for Google Stock? $200 or $400? (GOOG)
- Baird Maintains a 'Neutral' on MannKind (MNKD), Sees $1 Upside in Near-Term
- Cramer Gives a "Don't Buy" on First Solar (FSLR)
- Perma-Bull on Apple (AAPL) Cuts Price Target to $235
- Piper Jaffray Reiterates a 'Buy' on Apple (AAPL), Lowers Price Target and FY09 Estimates
Lazard Capital upgrades ArthroCare (Nasdaq: ARTC) from Hold to Buy.
ArthroCare Corporation designs, develops, manufactures, and markets medical devices for use in soft-tissue surgery.
Related Categories
UpgradesStocks Mentioned
-0.22Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
